search
Back to results

Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial (HOME-PE)

Primary Purpose

Pulmonary Embolism

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
HESTIA
sPESI
Sponsored by
University Hospital, Angers
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pulmonary Embolism

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Admission to Emergency Department or unscheduled consultation in one of the participating centres;
  • Symptomatic pulmonary embolism objectively confirmed according to the European Society of Cardiology criteria
  • Insurance cover according to local legislation;
  • Age ≥18 years;
  • Free informed consent according to local legislation

Exclusion Criteria:

  • Shock or hypotension defined as systolic blood pressure <90 mmHg or a systolic pressure drop by ≥40 mmHg, for >15 minutes, if not caused by new-onset arrhythmia, hypovolaemia, or sepsis;
  • Diagnosis of pulmonary embolism established more than 24H before inclusion;
  • More than 48h between first presentation to the Emergency unit and inclusion - - Factors rendering 30-day follow-up impossible;

Sites / Locations

  • Cliniques Universitaires Saint-Luc
  • Hôpital Erasme
  • Hôpital Saint-Pierre
  • CHU de Liège
  • Hôpital de Namur
  • Angers University Hospital
  • Hia Brest
  • CHU Brest
  • CHU Clermont-Ferrand
  • APHP Louis Mourier
  • CHU Dijon
  • CHU Grenoble
  • Thibault Schotté
  • CHU de Montpellier
  • APHP Cochin
  • APHP Hôpital Européen Georges Pompidou
  • APHP Lariboisière
  • CHU de Rouen
  • CHU Saint Etienne
  • CH Toulon
  • CHU Toulouse
  • Red Cross Hospital
  • TERGOOI
  • Leiden University Medical Center Leiden,
  • University Medical Center Utrecht
  • Ramon y Cajal Hospital
  • Hôpital de Genève
  • Hôpital de Lausanne

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

HESTIA group

sPESI group

Arm Description

Outcomes

Primary Outcome Measures

The rate of the composite of recurrent VTE, major bleeding and all cause death at 30 days
Recurrent VTE: objectively confirmed pulmonary embolism or deep venous thrombosis objectively confirmed. Major bleeding: according to the International Society on Thrombosis and Haemostasis' criteria. Death: all-cause mortality.

Secondary Outcome Measures

The rate of patients actually managed as outpatients (meaning patients discharged home within 24 hours after the inclusion in the study (first major secondary objective))
The rate of patients managed as outpatients defined by patients discharged home within 24 hours after the inclusion in the study.
The rate of "low-risk" patients in theory eligible for outpatient care (second major secondary objective)
The rate of "low-risk" patients eligible for outpatient care: HESTIA group: patients meeting none of the exclusion criteria of the rule (HESTIA rule negative); sPESI group: patients with a simplified PESI score =0.
Safety endpoints - Rate of cumulative events
The rate of the composite of recurrent VTE, major bleeding and all-cause death,
Safety endpoints - Recurrent VTE
The rate of recurrent VTE
Safety endpoints - Suspected recurrent VTE
The rate of recurrent VTE suspicion
Safety endpoints - Major Bleeding
The rate of major bleeding
Safety endpoints - Non major bleeding
The rate of non-major clinically relevant bleeding
Safety endpoints - Death
The rate of all-cause death
Safety endpoints - Serious adverse event
The rate of serious adverse event as defined in good clinical practice
Applicability of management strategies
The rate of patients actually managed as outpatients among number of patientpatients eligible for outpatient management
Resources utilization
Resources utilization will be assessed via the cumulative in-hospital length of stay (LOS) defined as the LOS for initial hospitalization plus LOS of possible unscheduled hospitalizations in the 30 days and 3 months following admission.
Patient satisfaction with care
A specific questionnaire will be used at 30 days following inclusion: - Anti-Clot Treatment - Specific Questionnaire (ACTS)
Patient quality of life
A specific questionnaire will be used at 30 days following inclusion: - Patient-reported Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL).

Full Information

First Posted
June 7, 2016
Last Updated
October 30, 2019
Sponsor
University Hospital, Angers
Collaborators
European Georges Pompidou Hospital, Hospital Universitario Ramon y Cajal, Leiden University Medical Center, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University of Lausanne Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT02811237
Brief Title
Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial
Acronym
HOME-PE
Official Title
Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
January 2017 (Actual)
Primary Completion Date
July 2019 (Actual)
Study Completion Date
October 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers
Collaborators
European Georges Pompidou Hospital, Hospital Universitario Ramon y Cajal, Leiden University Medical Center, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University of Lausanne Hospitals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Several studies have demonstrated the possibility of outpatient management or early discharge for certain patients presenting acute pulmonary embolism (PE), providing a suitable structure is in place. The approach featured in the most recent guidelines on acute PE of the European Society of Cardiology, refers to an all-cause mortality risk assessment using the Pulmonary Embolism Severity Index (PESI) score or the simplified PESI score (sPESI). The sPESI takes into account demographics (age), patient history (cancer, cardiac or respiratory disease), and clinical data (systolic blood pressure, heart rate, oxygen saturation). Outpatient care is offered to low-risk patients, providing that all the conditions pertaining to start anticoagulant treatment and follow-up at home are met. An alternative approach based on a list of simple criteria has been developed as the one used in HESTIA study. The main criteria included in the HESTIA rule consist of absence of the following: hemodynamic instability, need for oxygen therapy, high-risk of hemorrhage, renal or liver failure, or other medical or social conditions requiring hospitalization. The investigators hereby propose comparing these two approaches in an open-label, controlled randomized international trial with blinded adjudication of endpoints. The main objective is to demonstrate, in normotensive PE patients, that a strategy based on the HESTIA rule compared to a strategy based on the simplified PESI score is at least as safe as regards the 30-day-rate of adverse events (recurrent VTE, major bleeding or death). The major secondary objectives are to demonstrate, in normotensive PE patients, that a strategy based on the HESTIA rule compared to a strategy based on the simplified PESI score is more effective : As regards the rate of patients eventually managed as outpatients. As regards the rate of patients, in theory, eligible for outpatient care,
Detailed Description
All patients admitted in the Emergency Department of the participating centres and diagnosed with PE will be eligible and assessed for potential inclusion. Included patients will be randomized into two groups (1:1) and stratified by centre. Data will be recorded in a computerized case report form (e-CRF) enabling the randomization. The HESTIA group will receive outpatient care proposal based on HESTIA criteria. The sPESI group will receive outpatient care proposal based on the simplified PESI score. Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF. Follow-up will occur within 72 hours after inclusion, at 14 days, 1 month, and 3 months in both groups to gather clinical event data (recurrent VTE, major bleeding, death), treatment data, unscheduled hospitalizations and patient satisfaction assessment results. The major objectives will test HESTIA based strategy versus sPESI based strategy in a hierarchical approach: step 1: non-inferiority analysis on the rate of adverse events, if yes, step 2: superiority analysis on the rate of patients managed as outpatients, if yes, step3: superiority analysis on the rate of patients, in theory, eligible for outpatient care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1975 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HESTIA group
Arm Type
Other
Arm Title
sPESI group
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
HESTIA
Intervention Description
Management based on the HESTIA rule: If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care. In the other cases, the patient will receive in-hospital care. Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.
Intervention Type
Other
Intervention Name(s)
sPESI
Intervention Description
Management based on the simplified PESI score: If the sPESI score =0, the proposed management will be outpatient care. In the other cases, the patient will receive in-hospital care. Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.
Primary Outcome Measure Information:
Title
The rate of the composite of recurrent VTE, major bleeding and all cause death at 30 days
Description
Recurrent VTE: objectively confirmed pulmonary embolism or deep venous thrombosis objectively confirmed. Major bleeding: according to the International Society on Thrombosis and Haemostasis' criteria. Death: all-cause mortality.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
The rate of patients actually managed as outpatients (meaning patients discharged home within 24 hours after the inclusion in the study (first major secondary objective))
Description
The rate of patients managed as outpatients defined by patients discharged home within 24 hours after the inclusion in the study.
Time Frame
1 day
Title
The rate of "low-risk" patients in theory eligible for outpatient care (second major secondary objective)
Description
The rate of "low-risk" patients eligible for outpatient care: HESTIA group: patients meeting none of the exclusion criteria of the rule (HESTIA rule negative); sPESI group: patients with a simplified PESI score =0.
Time Frame
1 day
Title
Safety endpoints - Rate of cumulative events
Description
The rate of the composite of recurrent VTE, major bleeding and all-cause death,
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Recurrent VTE
Description
The rate of recurrent VTE
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Suspected recurrent VTE
Description
The rate of recurrent VTE suspicion
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Major Bleeding
Description
The rate of major bleeding
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Non major bleeding
Description
The rate of non-major clinically relevant bleeding
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Death
Description
The rate of all-cause death
Time Frame
14 days, 30 days, 90 days
Title
Safety endpoints - Serious adverse event
Description
The rate of serious adverse event as defined in good clinical practice
Time Frame
14 days, 30 days, 90 days
Title
Applicability of management strategies
Description
The rate of patients actually managed as outpatients among number of patientpatients eligible for outpatient management
Time Frame
1 day
Title
Resources utilization
Description
Resources utilization will be assessed via the cumulative in-hospital length of stay (LOS) defined as the LOS for initial hospitalization plus LOS of possible unscheduled hospitalizations in the 30 days and 3 months following admission.
Time Frame
Day 90
Title
Patient satisfaction with care
Description
A specific questionnaire will be used at 30 days following inclusion: - Anti-Clot Treatment - Specific Questionnaire (ACTS)
Time Frame
30 days
Title
Patient quality of life
Description
A specific questionnaire will be used at 30 days following inclusion: - Patient-reported Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL).
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Admission to Emergency Department or unscheduled consultation in one of the participating centres; Symptomatic pulmonary embolism objectively confirmed according to the European Society of Cardiology criteria Insurance cover according to local legislation; Age ≥18 years; Free informed consent according to local legislation Exclusion Criteria: Shock or hypotension defined as systolic blood pressure <90 mmHg or a systolic pressure drop by ≥40 mmHg, for >15 minutes, if not caused by new-onset arrhythmia, hypovolaemia, or sepsis; Diagnosis of pulmonary embolism established more than 24H before inclusion; More than 48h between first presentation to the Emergency unit and inclusion - - Factors rendering 30-day follow-up impossible;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre-Marie ROY, MD.PhD
Organizational Affiliation
CHU d'Angers, France
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Olivier SANCHEZ, MD.PhD
Organizational Affiliation
APHP Hôpital Européen Georges Pompidou, Paris, France
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Menno HUISMAN, MD.PhD
Organizational Affiliation
Leiden University Medical Center, Leiden, The Netherlands
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David JIMENEZ, MD.PhD
Organizational Affiliation
Hospital Universitario Ramon y Cajal, Madrid, Spain
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andréa PENALOZA, MD.PhD
Organizational Affiliation
Clinique Unisersitaire Saint Luc, Brussels, Belgium
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Guy MEYER, MD.PhD
Organizational Affiliation
APHP Hôpital Européen Georges Pompidou, Paris, France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
EriK KLOK, MD
Organizational Affiliation
Leiden University Medical Center Leiden, the Netherlands
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Olivier HUGLI
Organizational Affiliation
Centre Hospitalier Universitaire Vaudois
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
Country
Belgium
Facility Name
Hôpital Erasme
City
Bruxelles
Country
Belgium
Facility Name
Hôpital Saint-Pierre
City
Bruxelles
Country
Belgium
Facility Name
CHU de Liège
City
Liege
Country
Belgium
Facility Name
Hôpital de Namur
City
Namur
Country
Belgium
Facility Name
Angers University Hospital
City
Angers
ZIP/Postal Code
49933
Country
France
Facility Name
Hia Brest
City
Brest
ZIP/Postal Code
29240
Country
France
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
CHU Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Facility Name
APHP Louis Mourier
City
Colombes
Country
France
Facility Name
CHU Dijon
City
Dijon
Country
France
Facility Name
CHU Grenoble
City
Grenoble
Country
France
Facility Name
Thibault Schotté
City
Le Mans
Country
France
Facility Name
CHU de Montpellier
City
Montpellier
Country
France
Facility Name
APHP Cochin
City
Paris
Country
France
Facility Name
APHP Hôpital Européen Georges Pompidou
City
Paris
Country
France
Facility Name
APHP Lariboisière
City
Paris
Country
France
Facility Name
CHU de Rouen
City
Rouen
Country
France
Facility Name
CHU Saint Etienne
City
Saint Etienne
Country
France
Facility Name
CH Toulon
City
Toulon
Country
France
Facility Name
CHU Toulouse
City
Toulouse
Country
France
Facility Name
Red Cross Hospital
City
Beverwijk
ZIP/Postal Code
1942 LE
Country
Netherlands
Facility Name
TERGOOI
City
Hilversum
ZIP/Postal Code
1213 XZ
Country
Netherlands
Facility Name
Leiden University Medical Center Leiden,
City
Leiden
Country
Netherlands
Facility Name
University Medical Center Utrecht
City
Utrecht
ZIP/Postal Code
3584 CX
Country
Netherlands
Facility Name
Ramon y Cajal Hospital
City
Madrid
Country
Spain
Facility Name
Hôpital de Genève
City
Geneve
Country
Switzerland
Facility Name
Hôpital de Lausanne
City
Lausanne
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
24035045
Citation
Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, Carrier M. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thromb Res. 2013 Nov;132(5):515-9. doi: 10.1016/j.thromres.2013.08.012. Epub 2013 Aug 28.
Results Reference
background
PubMed Identifier
23100493
Citation
Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2013 Jul;42(1):134-44. doi: 10.1183/09031936.00093712. Epub 2012 Oct 25.
Results Reference
background
PubMed Identifier
25173341
Citation
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. No abstract available. Erratum In: Eur Heart J. 2015 Oct 14;36(39):2666. Eur Heart J. 2015 Oct 14;36(39):2642.
Results Reference
background
PubMed Identifier
21703676
Citation
Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6. Epub 2011 Jun 22.
Results Reference
background
PubMed Identifier
21645235
Citation
Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, de Vreede MJ, Huisman MV; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011 Aug;9(8):1500-7. doi: 10.1111/j.1538-7836.2011.04388.x.
Results Reference
background
PubMed Identifier
34363386
Citation
Roy PM, Penaloza A, Hugli O, Klok FA, Arnoux A, Elias A, Couturaud F, Joly LM, Lopez R, Faber LM, Daoud-Elias M, Planquette B, Bokobza J, Viglino D, Schmidt J, Juchet H, Mahe I, Mulder F, Bartiaux M, Cren R, Moumneh T, Quere I, Falvo N, Montaclair K, Douillet D, Steinier C, Hendriks SV, Benhamou Y, Szwebel TA, Pernod G, Dublanchet N, Lapebie FX, Javaud N, Ghuysen A, Sebbane M, Chatellier G, Meyer G, Jimenez D, Huisman MV, Sanchez O; HOME-PE Study Group. Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. Eur Heart J. 2021 Aug 31;42(33):3146-3157. doi: 10.1093/eurheartj/ehab373.
Results Reference
derived

Learn more about this trial

Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial

We'll reach out to this number within 24 hrs